STOCK TITAN
  1. Home
  2. Sec-filings
  3. NAMS
  4. [Form 4] NewAmsterdam Pharma Co N.V. Insider Trading Activity

NewAmsterdam Pharma (NAMS) director gets RSUs and options grant

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

NewAmsterdam Pharma Co N.V. director Louis G. Lange reported equity awards granted on January 7, 2026. He received 3,400 restricted stock units, each representing a contingent right to one ordinary share, granted for no consideration and scheduled to vest on the one-year anniversary of the vesting start date, subject to his continued service.

On the same date, he was granted an option to purchase 15,300 ordinary shares at an exercise price of $35.45 per share. All shares underlying this option are scheduled to vest on January 2, 2027, also contingent on continued service. Following these awards, he beneficially owned 10,360 ordinary shares and 15,300 options directly.

Positive

  • None.

Negative

  • None.
Insider LANGE LOUIS G
Role Director
Type Security Shares Price Value
Grant/Award Option (right to buy) 15,300 $0.00 --
Grant/Award Ordinary Shares 3,400 $0.00 --
Holdings After Transaction: Option (right to buy) — 15,300 shares (Direct); Ordinary Shares — 10,360 shares (Direct)
Footnotes (1)
  1. Represents restricted stock units (RSUs), each representing a contingent right to receive one ordinary share. All of the RSUs will vest on the one-year anniversary of the vesting start date, subject to the Reporting Person's continued service through such date. Each RSU was granted on January 7, 2026 for no consideration. The Reporting Person inadvertently reported the ownership of 3,102 ordinary shares issued upon vesting of RSUs on March 28, 2025 to his direct holdings. Such ordinary shares are held directly by LGLange III Trust DTD10 for the benefit of the Reporting Person. The Reporting Person subsequently corrected his indirect holdings on April 21, 2025, and the Reporting Person's indirect holdings reported on May 2, 2025 and June 3, 2025 are correct. This Form 4 reflects the Reporting Person's correct direct holdings. All of the ordinary shares underlying the option will vest on January 2, 2027, the one-year anniversary of the vesting start date, subject to the Reporting Person's continued service through such date.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
LANGE LOUIS G
(Last) (First) (Middle)
C/O NEWAMSTERDAM PHARMA COMPANY N.V.
GOOIMEER 2-35
(Street)
NAARDEN P7 1411 DC
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
NewAmsterdam Pharma Co N.V. [ NAMS ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
01/07/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Ordinary Shares 01/07/2026 A 3,400(1) A (2) 10,360(3) D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Option (right to buy) $35.45 01/07/2026 A 15,300 (4) 01/07/2036 Ordinary Shares 15,300 $0.00 15,300 D
Explanation of Responses:
1. Represents restricted stock units (RSUs), each representing a contingent right to receive one ordinary share. All of the RSUs will vest on the one-year anniversary of the vesting start date, subject to the Reporting Person's continued service through such date.
2. Each RSU was granted on January 7, 2026 for no consideration.
3. The Reporting Person inadvertently reported the ownership of 3,102 ordinary shares issued upon vesting of RSUs on March 28, 2025 to his direct holdings. Such ordinary shares are held directly by LGLange III Trust DTD10 for the benefit of the Reporting Person. The Reporting Person subsequently corrected his indirect holdings on April 21, 2025, and the Reporting Person's indirect holdings reported on May 2, 2025 and June 3, 2025 are correct. This Form 4 reflects the Reporting Person's correct direct holdings.
4. All of the ordinary shares underlying the option will vest on January 2, 2027, the one-year anniversary of the vesting start date, subject to the Reporting Person's continued service through such date.
/s/ Louise Kooij by Power of Attorney from Louis G. Lange 01/09/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did NewAmsterdam Pharma (NAMS) disclose for Louis G. Lange?

The company reported that director Louis G. Lange received 3,400 restricted stock units and an option to purchase 15,300 ordinary shares on January 7, 2026. Both awards were granted for no consideration and vest over time, subject to his continued service.

How many NewAmsterdam Pharma (NAMS) RSUs were granted to the director?

The director received 3,400 restricted stock units (RSUs), each representing a contingent right to receive one ordinary share. All of these RSUs will vest on the one-year anniversary of the vesting start date, as long as he continues to serve through that date.

What stock options were granted in this NewAmsterdam Pharma (NAMS) filing?

The filing shows an option grant for 15,300 ordinary shares with an exercise price of $35.45 per share. All shares underlying this option are scheduled to vest on January 2, 2027, contingent on the director's continued service.

Were the NewAmsterdam Pharma (NAMS) RSUs and options granted for cash consideration?

No. The filing states that each RSU was granted for no consideration, and the options were also reported with a price of $0.00 per derivative security at grant, reflecting that they were awarded as equity compensation rather than purchased for cash.

What are Louis G. Lange’s NewAmsterdam Pharma (NAMS) holdings after these transactions?

After the January 7, 2026 awards, the director beneficially owned 10,360 ordinary shares directly and 15,300 options to acquire additional ordinary shares, as reported in the filing.

What vesting conditions apply to the NewAmsterdam Pharma (NAMS) director’s equity awards?

The RSUs vest on the one-year anniversary of the vesting start date, and all shares under the option vest on January 2, 2027. In both cases, vesting is subject to the director’s continued service through the applicable vesting date.